Menu Search
Equities

M3 Inc

4YC:DUS

M3 Inc

Actions
  • Price (EUR)8.55
  • Today's Change-0.150 / -1.72%
  • Shares traded610.00
  • 1 Year change-40.63%
  • Beta--
Data delayed at least 15 minutes, as of Nov 25 2024 08:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

M3 Inc is a Japan-based company mainly engaged in the provision of services centering on the platform of healthcare. The Company has five business segments. Medical Platforms segment conducts marketing-related businesses in Japan utilizing the Internet and real operations centered on medical employee specialized site m3.com. Evidence Solution segment is involved in the contract research organization (CRO) business that supports clinical development work and research, and site management organization (SMO) business that manages the clinical trial operations. Career Solutions segment is engaged in human resource services for healthcare professionals. Site Solution segment provides operational support for medical institutions and home-visit nursing services. Overseas segment provides services of medical related marketing support, research and careers, utilizing the medical employee specialized sites in the United States, the United Kingdom, China, Korea, India, France, Germany and Spain.

  • Revenue in JPY (TTM)247.91bn
  • Net income in JPY39.16bn
  • Incorporated2000
  • Employees12.10k
  • Location
    M3 Inc10FAkasaka Inter City, 1-11-44, AkasakaMINATO-KU 107-0052JapanJPN
  • Phone+81 362298900
  • Fax+81 362298922
  • Websitehttps://corporate.m3.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		2413:TYO since
announced		Transaction
value
ELAN CorpDeal completed19 Sep 202419 Sep 2024Deal completed-0.81%243.64m
Data delayed at least 20 minutes, as of Nov 25 2024 06:30 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.